A Phase 2 interventional study of eltrombopag in Purpura, Thrombocytopaenic, Idiopathic, sponsored by GlaxoSmithKline. Completed at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-07-30.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic — 7 open to participants now, 7 under way, none of them phase 3. eltrombopag · Purpura, Thrombocytopenic, Idiopathic.
Among the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, this one is the 15th largest by enrollment, is one of 3 that started in 2007, is one of 15 in phase 2, and was the 4th registered.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →7 of the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:
Sohag University · Sites in Egypt
Ages 18–75
Renata PLC · Sites in Bangladesh
Ages 18–70
Nahda University · Sites in Egypt
Ages 18–65
Novartis Pharmaceuticals
Ages 5–17
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–80
By country, each count listing its studies:
eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 16 · Phase 3 9 · Phase 4 5
First in 2005; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 66 is above the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 40 across the 36 interventional studies. Of the 25 that completed or were terminated, 14 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 36 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
11 studies in Purpura, Thrombocytopenic, Idiopathic by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 11 finished, 6 (55%) have results posted.
Among the 11 studies in Purpura, Thrombocytopenic, Idiopathic by GlaxoSmithKline, this one is the 5th largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2007, is one of 4 in phase 2, and was the 3rd registered.
GlaxoSmithKline’s Purpura, Thrombocytopenic, Idiopathic studies by the year they started, since 2005.
1 of the studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07189910Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologySequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP | 2027-11-01 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 11 in Purpura, Thrombocytopenic, Idiopathic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This open-label, repeat dosing study, TRA108057, will evaluate the efficacy, safety and tolerability of eltrombopag, when administered in a repeat, cyclic dosing schedule. The study will describe the effect of repeated (3 cycles), intermittent dosing of eltrombopag on the pharmacodynamics and durability of eltrombopag response as measured by the peripheral platelet counts.
For more information or to see if you qualify, please visit: http://www.itpstudy.com/gov
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
This study's enrollment of 66 is above the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Browse Purpura, Thrombocytopenic, Idiopathic studies →GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
Compared within Purpura, Thrombocytopenic, Idiopathic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Purpura. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects eligible for enrolment in the study must meet all of the following criteria:
It is important to clearly differentiate the effect of eltrombopag on platelet count from the treatment effects of prior and concomitant ITP therapies. Therefore:
Complete abstinence from intercourse; Intrauterine device (IUD); Two forms of barrier contraception (diaphragm plus spermicide, and for males condom plus spermicide); Male partner is sterile prior to entry into the study and is the only partner of the female; Systemic contraceptives (combined or progesterone only).
Exclusion Criteria:
A subject will NOT be eligible for inclusion in this study if any of the following criteria apply:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: eltrombopag
experimental
Number of Participants Who Responded (Platelet Count >=50 Gi/L and >=2x Baseline) to Eltrombopag Treatment in Cycle 2 or Cycle 3 Given Participants Responded in Cycle 1
Complete blood count, platelet count by blood draw
Time frame: Day 42 of each cycle
Number of Participants Who Responded (Platelet Count Greater Than or Equal to 50 Gi/L and at Least 2x Baseline) for at Least 80 Percent of Their On-therapy Assessments During Weeks 2-6.
CBC, platelet counts
Time frame: Up to 42 days of dosing
Changes in Participants' Platelet Counts During 3 Cycles of Treatment
Changes from baseline, during on-therapy periods of a cycle, during off-therapy periods of a cycle, and within 4 weeks of permanent discontinuation of eltrombopag treatment.
Time frame: Up to 1 year
Number of Participants Who Required Rescue Medication
New idiopathic thrombocytopenic purpura (ITP) medication, increase dose of a concomitant ITP medication from baseline, platelet transfusion, and/or splenectomy
Time frame: Up to 3 cycles of treatment including follow-up visits following last dose of eltrombopag
Change in Participants Anti-platelet Antibody Levels From Baseline Through Follow-up
Change in participants' anti-platelet antibody levels was measured as the number of samples positive for at least 1 glycoprotein from baseline to follow-up. Serum glycoprotein-specific antigens: GPIIb/IIIa, Ib/IX, and Ia/IIa
Time frame: Up to 1 year
Number of Participants With the Indicated Bleeding Signs and Symptoms Using the World Health Organization Bleeding Scale
World health Organization (WHO) Bleeding Scale Grade 0 = no bleeding, Grade 1 = petechiae, Grade 2 = mild blood loss, Grade 3 = gross blood loss, Grade 4 = debilitating blood loss.
Time frame: Baseline, on-treatment visits (Weeks 1-6), off-treatment visits (Weeks 1-4)
Number of Participants With the Indicated Bleeding Signs and Symptoms Using the ITP Bleeding Score
ITP Bleeding Score: Grade 0 = no bleeding, Grade 1 = mild bleeding, Grade 2 = severe bleeding
Time frame: Baseline, on-treatment visits (Weeks 1-6), off-treatment visits (Weeks 1-4)
| Milestone | Treatment Period |
|---|---|
| Started | 66 |
| Completed | 55 |
| Not completed | 11 |
| Withdrew: Lack of efficacy | 8 |
| Withdrew: Adverse event | 1 |
| Withdrew: Prolonged response | 1 |
| Withdrew: Relocation | 1 |
| Milestone | Treatment Period |
|---|---|
| Started | 55 |
| Completed | 51 |
| Not completed | 4 |
| Withdrew: Lack of efficacy | 2 |
| Withdrew: Prolonged response | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Milestone | Treatment Period |
|---|---|
| Started | 51 |
| Completed | 48 |
| Not completed | 3 |
| Withdrew: Lack of efficacy | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Physician decision | 1 |
Complete blood count, platelet count by blood draw
| participants | Cycle 1 | Cycle 2 | Cycle 3 |
|---|---|---|---|
| Responders | 52 | 41 | 38 |
| Non-responders | 0 | 10 | 11 |
CBC, platelet counts
| participants | Cycle 1 | Cycle 2 | Cycle 3 |
|---|---|---|---|
| At least 80 percent of assessments met criteria | 38 | 35 | 30 |
| Less than 80 percent of assessments met criteria | 10 | 10 | 13 |
Changes from baseline, during on-therapy periods of a cycle, during off-therapy periods of a cycle, and within 4 weeks of permanent discontinuation of eltrombopag treatment.
| Gi/L | Cycle 1 | Cycle 2 | Cycle 3 |
|---|---|---|---|
| Baseline platelet count | 33.0 (7.0 to 82.0) | 25.0 (0 to 66.0) | 26.0 (8.0 to 167.0) |
| Highest on-therapy platelet count | 200.5 (52.0 to 762.0) | 196.0 (31.0 to 613.0) | 174.0 (10.0 to 366.0) |
| Lowest on-therapy platelet count | 72.0 (6.0 to 354.0) | 67.5 (7.0 to 454.0) | 59.0 (2.0 to 344.0) |
| Highest off-therapy platelet count | 118.5 (0 to 662.0) | 92.5 (12.0 to 701.0) | 125.0 (21.0 to 594.0) |
| Lowest off-therapy platelet count | 21.0 (0 to 59.0) | 22.5 (8.0 to 75.0) | 22.0 (0 to 187.0) |
New idiopathic thrombocytopenic purpura (ITP) medication, increase dose of a concomitant ITP medication from baseline, platelet transfusion, and/or splenectomy
| participants | Cycle 1 | Cycle 2 | Cycle 3 |
|---|---|---|---|
| Participants who required rescue treatment | 2 | 2 | 10 |
| Participants who did not require rescue treatment | 64 | 53 | 41 |
Change in participants' anti-platelet antibody levels was measured as the number of samples positive for at least 1 glycoprotein from baseline to follow-up. Serum glycoprotein-specific antigens: GPIIb/IIIa, Ib/IX, and Ia/IIa
| participants | Overall Study |
|---|---|
| Baseline | 12 |
| Cycle 2 on-therapy | 6 |
| Cycle 3 on-therapy | 7 |
| 4-week follow-up | 8 |
| 3-month follow-up | 1 |
| 6-month follow-up | 3 |
World health Organization (WHO) Bleeding Scale Grade 0 = no bleeding, Grade 1 = petechiae, Grade 2 = mild blood loss, Grade 3 = gross blood loss, Grade 4 = debilitating blood loss.
| participants | Cycle 1 | Cycle 2 | Cycle 3 |
|---|---|---|---|
| On-therapy, Week 0 (Day 1), n | 52 | 52 | 49 |
| On-therapy, Week 0, Grade 0 | 26 | 21 | 32 |
| On-therapy, Week 0, Grades 1-4 | 26 | 31 | 17 |
| On-therapy, Week 0, Grades 2-4 | 10 | 10 | 6 |
| On-therapy, Week 1 (Day 8), n | 51 | 51 | 49 |
| On-therapy, Week 1, Grade 0 | 34 | 36 | 37 |
| On-therapy, Week 1, Grades 1-4 | 17 | 15 | 12 |
| On-therapy, Week 1, Grades 2-4 | 4 | 2 | 3 |
| On-therapy, Week 2 (Day 15), n | 47 | 45 | 43 |
| On-therapy, Week 2, Grade 0 | 35 | 38 | 32 |
| On-therapy, Week 2, Grades 1-4 | 12 | 7 | 11 |
| On-therapy, Week 2, Grades 2-4 | 4 | 2 | 4 |
| On-therapy, Week 3 (Day 22), n | 33 | 32 | 33 |
| On-therapy, Week 3, Grade 0 | 28 | 25 | 26 |
| On-therapy, Week 3, Grades 1-4 | 5 | 7 | 7 |
| On-therapy, Week 3, Grades 2-4 | 3 | 2 | 2 |
| On-therapy, Week 4 (Day 29), n | 31 | 28 | 29 |
| On-therapy, Week 4, Grade 0 | 23 | 22 | 24 |
| On-therapy, Week 4, Grade 1-4 | 8 | 6 | 5 |
| On-therapy, Week 4, Grade 2-4 | 2 | 2 | 0 |
| On-therapy, Week 5 (Day 36), n | 28 | 26 | 29 |
| On-therapy, Week 5, Grade 0 | 24 | 20 | 24 |
| On-therapy, Week 5, Grades 1-4 | 4 | 6 | 5 |
| On-therapy, Week 5, Grades 2-4 | 1 | 3 | 1 |
| On-therapy, Week 6 (Day 43), n | 25 | 26 | 27 |
| On-therapy, Week 6, Grade 0 | 22 | 22 | 22 |
| On-therapy, Week 6, Grades 1-4 | 3 | 4 | 5 |
| On-therapy, Week 6, Grades 2-4 | 0 | 4 | 1 |
| Off-therapy, Week 1 (Day 8), n | 47 | 45 | 46 |
| Off-therapy, Week 1, Grade 0 | 37 | 35 | 42 |
| Off-therapy, Week 1, Grades 1-4 | 10 | 10 | 4 |
| Off-therapy, Week 1, Grades 2-4 | 4 | 4 | 0 |
| Off-therapy, Week 2 (Day 15), n | 37 | 35 | 45 |
| Off-therapy, Week 2, Grade 0 | 26 | 25 | 30 |
| Off-therapy, Week 2, Grades 1-4 | 11 | 10 | 15 |
| Off-therapy, Week 2, Grades 2-4 | 2 | 3 | 2 |
| Off-therapy, Week 3 (Day 22), n | 28 | 30 | 46 |
| Off-therapy, Week 3, Grade 0 | 18 | 19 | 30 |
| Off-therapy, Week 3, Grades 1-4 | 10 | 11 | 16 |
| Off-therapy, Week 3, Grades 2-4 | 2 | 4 | 7 |
| Off-therapy, Week 4 (Day 29), n | 7 | 12 | 48 |
| Off-therapy, Week 4, Grade 0 | 5 | 9 | 30 |
| Off-therapy, Week 4, Grades 1-4 | 2 | 3 | 18 |
| Off-therapy, Week 4, Grades 2-4 | 1 | 2 | 6 |
ITP Bleeding Score: Grade 0 = no bleeding, Grade 1 = mild bleeding, Grade 2 = severe bleeding
| participants | Cycle 1 | Cycle 2 | Cycle 3 |
|---|---|---|---|
| Skin, petechiae, on-therapy, Week 0 (Day 1), n | 50 | 52 | 49 |
| Skin, petechiae, on-therapy, Week 0, Grade 0 | 35 | 35 | 39 |
| Skin, petechiae, on-therapy, Week 0, Grade 1 | 14 | 17 | 10 |
| Skin, petechiae, on-therapy, Week 0, Grade 2 | 1 | 0 | 0 |
| Skin, petechiae, on-therapy, Week 1 (Day 8), n | 51 | 51 | 48 |
| Skin, petechiae, on-therapy, Week 1, Grade 0 | 41 | 46 | 44 |
| Skin, petechiae, on-therapy, Week 1, Grade 1 | 10 | 3 | 3 |
| Skin, petechiae, on-therapy, Week 1, Grade 2 | 0 | 2 | 1 |
| Skin, petechiae, on-therapy, Week 2 (Day 15), n | 47 | 45 | 42 |
| Skin, petechiae, on-therapy, Week 2, Grade 0 | 40 | 43 | 39 |
| Skin, petechiae, on-therapy, Week 2, Grade 1 | 7 | 2 | 2 |
| Skin, petechiae, on-therapy, Week 2, Grade 2 | 0 | 0 | 1 |
| Skin, petechiae, on-therapy, Week 3 (Day 22), n | 33 | 32 | 33 |
| Skin, petechiae, on-therapy, Week 3, Grade 0 | 31 | 28 | 32 |
| Skin, petechiae, on-therapy, Week 3, Grade 1 | 2 | 4 | 1 |
| Skin, petechiae, on-therapy, Week 3, Grade 2 | 0 | 0 | 0 |
| Skin, petechiae, on-therapy, Week 4 (Day 29), n | 31 | 28 | 29 |
| Skin, petechiae, on-therapy, Week 4, Grade 0 | 30 | 24 | 28 |
| Skin, petechiae, on-therapy, Week 4, Grade 1 | 1 | 4 | 1 |
| Skin, petechiae, on-therapy, Week 4, Grade 2 | 0 | 0 | 0 |
| Skin, petechiae, on-therapy, Week 5 (Day 36), n | 28 | 26 | 29 |
| Skin, petechiae, on-therapy, Week 5, Grade 0 | 27 | 21 | 29 |
| Skin, petechiae, on-therapy, Week 5, Grade 1 | 1 | 5 | 0 |
| Skin, petechiae, on-therapy, Week 5, Grade 2 | 0 | 0 | 0 |
| Skin, petechiae, on-therapy, Week 6 (Day 43), n | 24 | 25 | 27 |
| Skin, petechiae, on-therapy, Week 6, Grade 0 | 24 | 23 | 27 |
| Skin, petechiae, on-therapy, Week 6, Grade 1 | 0 | 2 | 0 |
| Skin, petechiae, on-therapy, Week 6, Grade 2 | 0 | 0 | 0 |
| Skin, petechiae, off-therapy, Week 1 (Day 8), n | 47 | 45 | 48 |
| Skin, petechiae, off-therapy, Week 1, Grade 0 | 45 | 39 | 45 |
| Skin, petechiae, off-therapy, Week 1, Grade 1 | 2 | 6 | 3 |
| Skin, petechiae, off-therapy, Week 1, Grade 2 | 0 | 0 | 0 |
| Skin, petechiae, off-therapy, Week 2 (Day 15), n | 36 | 35 | 45 |
| Skin, petechiae, off-therapy, Week 2, Grade 0 | 31 | 30 | 40 |
| Skin, petechiae, off-therapy, Week 2, Grade 1 | 5 | 5 | 4 |
| Skin, petechiae, off-therapy, Week 2, Grade 2 | 0 | 0 | 1 |
| Skin, petechiae, off-therapy, Week 3 (Day 22), n | 29 | 30 | 46 |
| Skin, petechiae, off-therapy, Week 3, Grade 0 | 27 | 26 | 39 |
| Skin, petechiae, off-therapy, Week 3, Grade 1 | 2 | 4 | 7 |
| Skin, petechiae, off-therapy, Week 3, Grade 2 | 0 | 0 | 0 |
| Skin, petechiae, off-therapy, Week 4 (Day 29), n | 7 | 12 | 48 |
| Skin, petechiae, off-therapy, Week 4, Grade 0 | 7 | 12 | 41 |
| Skin, petechiae, off-therapy, Week 4, Grade 1 | 0 | 0 | 6 |
| Skin, petechiae, off-therapy, Week 4, Grade 2 | 0 | 0 | 1 |
| Skin, ecchymosis, on-therapy, Week 0 (Day 1), n | 50 | 52 | 49 |
| Skin, ecchymosis, on-therapy, Week 0, Grade 0 | 31 | 27 | 36 |
| Skin, ecchymosis, on-therapy, Week 0, Grade 1 | 16 | 25 | 12 |
| Skin, ecchymosis, on-therapy, Week 0, Grade 2 | 3 | 0 | 1 |
| Skin, ecchymosis, on-therapy, Week 1 (Day 8), n | 51 | 51 | 48 |
| Skin, ecchymosis, on-therapy, Week 1, Grade 0 | 39 | 37 | 35 |
| Skin, ecchymosis, on-therapy, Week 1, Grade 1 | 11 | 13 | 12 |
| Skin, ecchymosis, on-therapy, Week 1, Grade 2 | 1 | 1 | 1 |
| Skin, ecchymosis, on-therapy, Week 2 (Day 15), n | 47 | 45 | 42 |
| Skin, ecchymosis, on-therapy, Week 2, Grade 0 | 42 | 38 | 32 |
| Skin, ecchymosis, on-therapy, Week 2, Grade 1 | 5 | 7 | 9 |
| Skin, ecchymosis, on-therapy, Week 2, Grade 2 | 0 | 0 | 1 |
| Skin, ecchymosis, on-therapy, Week 3 (Day 22), n | 33 | 32 | 33 |
| Skin, ecchymosis, on-therapy, Week 3, Grade 0 | 28 | 24 | 29 |
| Skin, ecchymosis, on-therapy, Week 3, Grade 1 | 5 | 8 | 4 |
| Skin, ecchymosis, on-therapy, Week 3, Grade 2 | 0 | 0 | 0 |
| Skin, ecchymosis, on-therapy, Week 4 (Day 29), n | 31 | 28 | 29 |
| Skin, ecchymosis, on-therapy, Week 4, Grade 0 | 24 | 24 | 25 |
| Skin, ecchymosis, on-therapy, Week 4, Grade 1 | 7 | 4 | 4 |
| Skin, ecchymosis, on-therapy, Week 4, Grade 2 | 0 | 0 | 0 |
| Skin, ecchymosis, on-therapy, Week 5 (Day 36), n | 28 | 26 | 29 |
| Skin, ecchymosis, on-therapy, Week 5, Grade 0 | 25 | 23 | 25 |
| Skin, ecchymosis, on-therapy, Week 5, Grade 1 | 3 | 3 | 4 |
| Skin, ecchymosis, on-therapy, Week 5, Grade 2 | 0 | 0 | 0 |
| Skin, ecchymosis, on-therapy, Week 6 (Day 43), n | 24 | 25 | 27 |
| Skin, ecchymosis, on-therapy, Week 6, Grade 0 | 20 | 22 | 25 |
| Skin, ecchymosis, on-therapy, Week 6, Grade 1 | 4 | 3 | 2 |
| Skin, ecchymosis, on-therapy, Week 6, Grade 2 | 0 | 0 | 0 |
| Skin, ecchymosis, off-therapy, Week 1 (Day 1), n | 47 | 45 | 48 |
| Skin, ecchymosis, off-therapy, Week 1, Grade 0 | 42 | 38 | 43 |
| Skin, ecchymosis, off-therapy, Week 1, Grade 1 | 5 | 7 | 5 |
| Skin, ecchymosis, off-therapy, Week 1, Grade 2 | 0 | 0 | 0 |
| Skin, ecchymosis, off-therapy, Week 2 (Day 15), n | 36 | 35 | 45 |
| Skin, ecchymosis, off-therapy, Week 2, Grade 0 | 26 | 24 | 36 |
| Skin, ecchymosis, off-therapy, Week 2, Grade 1 | 9 | 11 | 9 |
| Skin, ecchymosis, off-therapy, Week 2, Grade 2 | 1 | 0 | 0 |
| Skin, ecchymosis, off-therapy, Week 3 (Day 22), n | 29 | 30 | 46 |
| Skin, ecchymosis, off-therapy, Week 3, Grade 0 | 16 | 20 | 31 |
| Skin, ecchymosis, off-therapy, Week 3, Grade 1 | 11 | 9 | 13 |
| Skin, ecchymosis, off-therapy, Week 3, Grade 2 | 2 | 1 | 2 |
| Skin, ecchymosis, off-therapy, Week 4 (Day 29), n | 7 | 12 | 48 |
| Skin, ecchymosis, off-therapy, Week 4, Grade 0 | 6 | 9 | 31 |
| Skin, ecchymosis, off-therapy, Week 4, Grade 1 | 0 | 3 | 15 |
| Skin, ecchymosis, off-therapy, Week 4, Grade 2 | 1 | 0 | 2 |
| Oral, on-therapy, Week 0 (Day 1), n | 50 | 52 | 49 |
| Oral, on-therapy, Week 0, Grade 0 | 46 | 46 | 46 |
| Oral, on-therapy, Week 0, Grade 1 | 4 | 5 | 3 |
| Oral, on-therapy, Week 0, Grade 2 | 0 | 1 | 0 |
| Oral, on-therapy, Week 1 (Day 8), n | 51 | 51 | 48 |
| Oral, on-therapy, Week 1, Grade 0 | 49 | 49 | 46 |
| Oral, on-therapy, Week 1, Grade 1 | 2 | 2 | 2 |
| Oral, on-therapy, Week 1, Grade 2 | 0 | 0 | 0 |
| Oral, on-therapy, Week 2 (Day 15), n | 47 | 45 | 42 |
| Oral, on-therapy, Week 2, Grade 0 | 46 | 43 | 41 |
| Oral, on-therapy, Week 2, Grade 1 | 1 | 2 | 1 |
| Oral, on-therapy, Week 2, Grade 2 | 0 | 0 | 0 |
| Oral, on-therapy, Week 3 (Day 22), n | 33 | 32 | 33 |
| Oral, on-therapy, Week 3, Grade 0 | 33 | 30 | 31 |
| Oral, on-therapy, Week 3, Grade 1 | 0 | 2 | 2 |
| Oral, on-therapy, Week 3, Grade 2 | 0 | 0 | 0 |
| Oral, on-therapy, Week 4 (Day 29), n | 31 | 28 | 29 |
| Oral, on-therapy, Week 4, Grade 0 | 30 | 26 | 29 |
| Oral, on-therapy, Week 4, Grade 1 | 1 | 2 | 0 |
| Oral, on-therapy, Week 4, Grade 2 | 0 | 0 | 0 |
| Oral, on-therapy, Week 5 (Day 36), n | 28 | 26 | 29 |
| Oral, on-therapy, Week 5, Grade 0 | 27 | 24 | 29 |
| Oral, on-therapy, Week 5, Grade 1 | 1 | 2 | 0 |
| Oral, on-therapy, Week 5, Grade 2 | 0 | 0 | 0 |
| Oral, on-therapy, Week 6 (Day 43), n | 24 | 25 | 27 |
| Oral, on-therapy, Week 6, Grade 0 | 23 | 23 | 26 |
| Oral, on-therapy, Week 6, Grade 1 | 1 | 2 | 1 |
| Oral, on-therapy, Week 6, Grade 2 | 0 | 0 | 0 |
| Oral, off-therapy, Week 1 (Day 8), n | 47 | 45 | 48 |
| Oral, off-therapy, Week 1, Grade 0 | 45 | 43 | 48 |
| Oral, off-therapy, Week 1, Grade 1 | 2 | 2 | 0 |
| Oral, off-therapy, Week 1, Grade 2 | 0 | 0 | 0 |
| Oral, off-therapy, Week 2 (Day 15), n | 36 | 35 | 45 |
| Oral, off-therapy, Week 2, Grade 0 | 36 | 35 | 45 |
| Oral, off-therapy, Week 2, Grade 1 | 0 | 3 | 3 |
| Oral, off-therapy, Week 2, Grade 2 | 0 | 0 | 0 |
| Oral, off-therapy, Week 3 (Day 22), n | 29 | 30 | 46 |
| Oral, off-therapy, Week 3, Grade 0 | 27 | 29 | 41 |
| Oral, off-therapy, Week 3, Grade 1 | 2 | 1 | 5 |
| Oral, off-therapy, Week 3, Grade 2 | 0 | 0 | 0 |
| Oral, off-therapy, Week 4 (Day 29), n | 7 | 12 | 48 |
| Oral, off-therapy, Week 4, Grade 0 | 7 | 10 | 45 |
| Oral, off-therapy, Week 4, Grade 1 | 0 | 2 | 2 |
| Oral, off-therapy, Week 4, Grade 2 | 0 | 0 | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cycle 1 | — | 0/66 (0%) | 39/66 (59.1%) |
| Cycle 2 | — | 1/55 (1.8%) | 30/55 (54.5%) |
| Cycle 3 | — | 0/51 (0%) | 38/51 (74.5%) |
| More Than 1 to 30 Days After Last Dose | — | 1/66 (1.5%) | 17/66 (25.8%) |
| More Than 30 Days After Last Dose | — | 1/66 (1.5%) | 7/66 (10.6%) |
| All Cycles | — | 4/66 (6.1%) | 55/66 (83.3%) |
| Event | Cycle 1 | Cycle 2 | Cycle 3 | More Than 1 to 30 Days After Last Dose | More Than 30 Days After Last Dose | All Cycles |
|---|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/66 | 1/55 | 0/51 | 0/66 | 0/66 | 1/66 |
| Abdominal pain upperGastrointestinal disorders | 0/66 | 0/55 | 0/51 | 1/66 | 0/66 | 1/66 |
| Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/66 | 0/55 | 0/51 | 1/66 | 0/66 | 1/66 |
| Ear hemorrhageEar and labyrinth disorders | 0/66 | 0/55 | 0/51 | 0/66 | 1/66 | 1/66 |
| Mouth HemorrhageGastrointestinal disorders | 0/66 | 0/55 | 0/51 | 0/66 | 1/66 | 1/66 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/66 | 0/55 | 0/51 | 0/66 | 1/66 | 1/66 |
| Event | Cycle 1 | Cycle 2 | Cycle 3 | More Than 1 to 30 Days After Last Dose | More Than 30 Days After Last Dose | All Cycles |
|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 9/66 | 10/55 | 7/51 | 5/66 | 0/66 | 16/66 |
| NasopharyngitisInfections and infestations | 5/66 | 2/55 | 5/51 | 3/66 | 1/66 | 10/66 |
| FatigueGeneral disorders | 1/66 | 5/55 | 7/51 | 3/66 | 0/66 | 10/66 |
| DiarrhoeaGastrointestinal disorders | 6/66 | 1/55 | 3/51 | 1/66 | 1/66 | 8/66 |
| Back painMusculoskeletal and connective tissue disorders | 3/66 | 4/55 | 1/51 | 0/66 | 0/66 | 7/66 |
| Upper respiratory tract infectionInfections and infestations | 2/66 | 1/55 | 3/51 | 3/66 | 0/66 | 5/66 |
| NauseaGastrointestinal disorders | 3/66 | 3/55 | 0/51 | 0/66 | 0/66 | 5/66 |
| VomitingGastrointestinal disorders | 2/66 | 2/55 | 1/51 | 0/66 | 0/66 | 5/66 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/66 | 1/55 | 1/51 | 1/66 | 0/66 | 5/66 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 3/66 | 0/55 | 2/51 | 0/66 | 0/66 | 5/66 |
| Age Continuous(years) | Overall Study Population |
|---|---|
| Mean | 49.6 ± 14.61 |
| Sex: Female, Male(Participants) | Overall Study Population |
|---|---|
| Female | 45 |
| Male | 21 |
| Race/Ethnicity, Customized(participants) | Overall Study Population |
|---|---|
| White - White/Caucasian/European | 47 |
| Asian - East Asian | 10 |
| White - Arabic/North African | 6 |
| African American/African | 2 |
| American Indian or Alaska Native | 1 |
| Baseline Platelet Count(participants) | Overall Study Population |
|---|---|
| Less than 20 giga per liter (Gi/L) | 4 |
| 20 Gi/L to 30 Gi/L | 29 |
| Greater than 30 Gi/L to 50 Gi/L | 31 |
| Greater than 50 Gi/L | 2 |
| Baseline Splenectomy Status(participants) | Overall Study Population |
|---|---|
| Yes | 20 |
| No | 46 |
| Use of Idiopathic Thrombocytopenic Purpura Medication at Baseline(participants) | Overall Study Population |
|---|---|
| Yes | 22 |
| No | 44 |
The record gives a start of Mar 2007, a primary completion of Aug 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2009, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eltrombopag
Purpura, Thrombocytopenic, Idiopathic →